Use of Androgen Lowering Medications Finasteride and Dutasteride Do Not Substantially Alter Risk of Incident HCV-Related Hepatocellular Carcinoma in Men

    May 2019 in “ Gastroenterology
    Donna L. White, Peter J. Richardson, Israel C. Christie, Sarah Plew, Li Jiao, Hashem B. El-Serag, Fasiha Kanwal, Jennifer R. Kramer
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Image
    Studysummary Androgen lowering medications don't significantly change HCV-related liver cancer risk in men. Our plain-language summary of this paper — not a Tressless recommendation.
    This document contains abstracts from several studies presented at a scientific conference. One study found that screening for hepatitis C virus (HCV) in an urban emergency department was effective in identifying infected patients, with a high rate of treatment and cure achieved through referral to a hepatology clinic. Another study found that there is modest concordance among non-invasive serum indices and imaging in HCV-related fibrosis, with lower BMI predicting agreement among non-invasive methods. A third study found that the use of androgen lowering medications finasteride and dutasteride does not substantially alter the risk of incident HCV-related hepatocellular carcinoma in men. Finally, a fourth study found that the albumin-bilirubin score can indicate liver fibrosis staging and prognosis in Japanese HCV infection patients.
    Discuss this study in the Community →